| Similar Articles |
|---|
 |
The Motley Fool
April 23, 2004
Charly Travers |
A Difficult Drug Launch Investors expected a lot from Fuzeon, Trimeris' HIV drug therapy. However, anticipated sales for the biotechnology company didn't materialize.   |
The Motley Fool
March 19, 2007
Brian Lawler |
Trimeris Gets Trimmed Shares of the drug developer are down after a management shakeup. With shares trading near their 52-week lows amid all the pessimism, now is a good time for less-risk adverse investors to buy in. |
The Motley Fool
July 19, 2007
Brian Orelli |
Trimeris Reaches a Plateau Drug developer Trimeris needs to push another drug out of its pipeline because sales of its only drug, Fuzeon, appear to be hitting the wall. Investors, take note. |
The Motley Fool
November 30, 2007
Brian Lawler |
Not What Trimeris Needs Small biopharma Trimeris revealed that it and partner Roche were being sued for patent infringement by Novartis over Trimeris' only marketed compound, Fuzeon. |
The Motley Fool
April 23, 2007
Brian Lawler |
Trimeris Isn't Tumbling Trimeris announces first-quarter sales numbers for its HIV drug Fuzeon. Shares of the company were up 25% last week after it reported stronger-than-expected sales of the fusion inhibitor. |
The Motley Fool
January 30, 2008
Brian Lawler |
The Competition Bites Trimeris Rivals lead to lower sales of the small specialty pharmaceutical's only marketed drug. |
The Motley Fool
November 20, 2006
Karl Thiel |
Trimeris Begs for a Buyout The pharmaceutical's reorganization plan practically posts a "for sale" sign. So will Roche -- or someone else -- bite? Investors, take note. |
The Motley Fool
August 15, 2007
Brian Lawler |
Call for Change at Trimeris A shareholder group criticizes tiny Trimeris about its spending on research. In an SEC filing, HealthCor, which owns 15% of the outstanding shares, called for the pharmaceutical company to cut back on its research and development expenses and to explore selling the company. |
The Motley Fool
May 2, 2007
Brian Lawler |
Progenics' Intriguing Study Results The development-stage drugmaker released clinical trial results for one of its compounds. Investors, take note. |
